Alnylam Pharmaceuticals | ALNY - Sales Revenues


Alnylam Pharmaceuticals reported $1.17B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Arrowhead Research USD 73.74M 190.29M Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Moderna USD 389M 289M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 750M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026
Xencor USD 4.51M 23.73M Mar/2026